Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.39 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MGMT | P16455 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azaserine SCHEMBL20520234 | 0.79 | ALDH1A1 (0.41) | TP53KDM4ETSHRHSD17B10SMN1; SMN2 | |
| Azaserine SCHEMBL81760 | 0.79 | ALDH1A1 (0.41) | TP53KDM4ETSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL4496030 | 0.73 | CDC7 (0.60) | CDC7DBF4PDPK1CDK1CDK2 | |
| SCHEMBL528456 | 0.73 | CDC7 (0.50) | CDC7DBF4PDPK1CDK1CDK2 | |
| SCHEMBL4397297 | 0.70 | PDPK1 (0.55) | CDC7DBF4PDPK1CDK1CDK2 | |
| SCHEMBL8187698 | 0.69 | PDPK1 (0.53) | CDC7DBF4PDPK1CDK1CDK2 | |
| SCHEMBL2938609 | 0.67 | PDPK1 (0.62) | CDC7DBF4PDPK1CDK1CDK2 | |
| SCHEMBL607081 | 0.66 | — | — | |
| Adenine SCHEMBL8511073 | 0.66 | CYP3A4 (0.44) | CDC7DBF4LMNAMGMTMAPT | |
| Azaserine SCHEMBL8861 | 0.65 | SLC1A5 (0.38) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240094218-A1 | ENHANCED HYBRIDOMA GENERATION | AMGEN INC. (US) | 2024-03-21 | — | — | US | claimed |
| EP-4288450-A1 | ENHANCED HYBRIDOMA GENERATION | Amgen Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| US-20240174758-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-05-30 | — | — | US | disclosed |
| US-20240094218-A1 | ENHANCED HYBRIDOMA GENERATION | AMGEN INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4308607-A2 | THERAPEUTIC BINDING MOLECULE THAT BINDS TO CCR9 | MedImmune Limited (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-4304647-A1 | ANTIBODIES DIRECTED AGAINST GDF-15 | MedImmune, LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11845791-B2 | Antibodies directed against GDF-15 | MEDIMMUNE, LLC (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4288450-A1 | ENHANCED HYBRIDOMA GENERATION | Amgen Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230322867-A1 | IMMUNOGENS DERIVED FROM SARS-COV2 SPIKE PROTEIN | AMGEN INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4185322-A2 | IMMUNOGENS DERIVED FROM SARS-COV2 SPIKE PROTEIN | Amgen Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220281965-A1 | ANTIBODIES DIRECTED AGAINST GDF-15 | MEDIMMUNE, LLC | 2022-09-08 | — | — | US | disclosed |
| US-5085985-A | Monoclonal antibodies and their use in a method for monitoring subsets of activated T cells | BECTON DICKINSON & CO. (US) | 1992-02-04 | — | — | US | disclosed |
| US-5070025-A | MEASUREMENT OF DEPOLARIZATION OF POLARIZED LIGHT PASSING THROU GH SOLUTION | BOEHRINGER MANNHEIM GMBH (DE) | 1991-12-03 | — | — | US | disclosed |
| US-5001065-A | Human cell line and triomas, antibodies, and transformants derived therefrom | CETUS CORPORATION (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0359282-A2 | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic compositions containing same | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1990-03-21 | — | — | EP | disclosed |
| US-4897466-A | MONOCLONAL ANTIBODIES FOR TREATING TETANUS | CETUS CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0292965-A2 | Human cell line and triomas, antibodes, and transformants derived therefrom | CETUS ONCOLOGY CORPORATION (US) | 1988-11-30 | — | — | EP | disclosed |
| US-4762783-A | Process and reagent for the determination of the follicle-stimulating hormone and monoclonal antibodies suitable therefor | BOEHRINGER MANNHEIM GMBH (DE) | 1988-08-09 | — | — | US | disclosed |
| US-4624921-A | CULTURES, FUSION | CETUS CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0160550-A2 | Human lymphoblastoid cell line and hybridomas derived therefrom and antibodies produced from such hybridomas, and the production and use of the aforesaid | CETUS CORPORATION (US) | 1985-11-06 | — | — | EP | disclosed |